Src as a therapeutic target in anti-hormone/anti-growth factor-resistant breast cancer

Endocrine-Related Cancer

Volumn 13, Issue SUPPL. 1, 2006, Pages

  Hiscox, Stephen ^a   Morgan, L ^a   Green, Tim ^b   Nicholson, Robert I ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

^b ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ABELSON KINASE; AZD 0530; CADHERIN; CATENIN; GEFITINIB; GROWTH FACTOR INHIBITOR; PROTEIN INHIBITOR; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; SRC KINASE; TAMOXIFEN; UNCLASSIFIED DRUG;

BREAST CANCER; CANCER GROWTH; CANCER INVASION; CANCER MORTALITY; CARCINOGENESIS; CELL ADHESION; CELL MIGRATION; CONFERENCE PAPER; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG SENSITIVITY; DRUG TARGETING; ENZYME INHIBITION; HORMONAL THERAPY; HUMAN; IN VITRO STUDY; PHENOTYPE; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CADHERINS; CARCINOMA; CATENINS; CELL ADHESION; CELL-MATRIX JUNCTIONS; DRUG RESISTANCE, NEOPLASM; EPIDERMAL GROWTH FACTOR; HUMANS; NEOPLASM INVASIVENESS; PROTO-ONCOGENE PROTEINS PP60(C-SRC);

EID: 33846870586     PISSN: 13510088     EISSN: None     Source Type: Journal    
DOI: 10.1677/erc.1.01297     Document Type: Conference Paper

References (63)

1. Aligayer H, Boyd DD, Heiss MM, Abdalla EK, Curley SA & Gallick GE 2002 Activation of Src kinase in primary colorectal carcinoma: an indicator of poor clinical prognosis. Cancer 94 344-351.
2. Arpino G, Green SJ, Allred DC, Lew D, Martino S, Osborne CK & Elledge RM 2004 HER-2 amplification, HER-1 expression, and tamoxifen response in estrogen receptor-positive metastatic breast cancer: a southwest oncology group study. Clinical Cancer Research 10 5670-5676.
3. Belsches-Jablonski AP, Biscardi JS, Peavy DR, Tice DA, Romney DA & Parsons SJ 2001 Src family kinases and HER2 interactions in human breast cancer cell growth and survival. Oncogene 20 1465-1475.
4. Benz CC, Scott GK, Sarup JC, Johnson RM, Tripathy D, Coronado E, Shepard HM & Osborne CK 1993 Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu. Breast Cancer Research and Treatment 24 85-95.
5. Biscardi JS, Ishizawar RC, Silva CM & Parsons SJ 2000 Tyrosine kinase signalling in breast cancer: epidermal growth factor receptor and c-Src interactions in breast cancer. Breast Cancer Research 2 203-210.
6. Bjorge JD, Pang A & Fujita DJ 2000 Identification of protein-tyrosine phosphatase 1B as the major tyrosine phosphatase activity capable of dephosphorylating and activating c-Src in several human breast cancer cell lines. Journal of Biological Chemistry 275 41439-41446.
7. Britton DJ, Hutcheson IR, Knowlden JM, Barrow D, Giles M, McClelland RA, Gee JM & Nicholson RI 2006 Bidirectional cross talk between ERalpha and EGFR signalling pathways regulates tamoxifen-resistant growth. Breast Cancer Research and Treatment 96 131-146.
8. Brunton VG, MacPherson IR & Frame MC 2004 Cell adhesion receptors, tyrosine kinases and actin modulators: a complex three-way circuitry. Biochimica et Biophysica Acta 1692 121-144.
9. Coluccia AM, Benati D, Dekhil H, De Filippo A, Lan C & Gambacorti-Passerini C 2006 SKI-606 decreases growth and motility of colorectal cancer cells by preventing pp60(c-Src)-dependent tyrosine phosphorylation of beta-catenin and its nuclear signaling. Cancer Research 66 2279-2286.
10. Fincham VJ & Frame MC 1998 The catalytic activity of Src is dispensable for translocation to focal adhesions but controls the turnover of these structures during cell motility. EMBO Journal 17 81-92.
11. Frame MC 2002 Src in cancer: deregulation and consequences for cell behaviour. Biochimica et Biophysica Acta 1602 114-130.
12. Gee JM, Howell A, Gullick WJ, Benz CC, Sutherland RL, Santen RJ, Martin LA, Ciardiello F, Miller WR, Dowsett M et al. 2005 Consensus statement. Workshop on therapeutic resistance in breast cancer: impact of growth factor signalling pathways and implications for future treatment. Endocrine-Related Cancer 12 (Suppl) S1-S7.
13. Gilmore AP & Romer LH 1996 Inhibition of focal adhesion kinase (FAK) signaling in focal adhesions decreases cell motility and proliferation. Molecular Biology of the Cell 7 1209-1224.
14. Gonzalez L, Manuel Garcia-Martinez J, Calcabrini A, Teresa Agullo M, Gamallo Amat C, Palacios Calvo J, Aranda A & Martin-Perez J 2006 Role of c-SRC in human MCF7 breast cancer cell tumorigenesis. Journal of Biological Chemistry 281 851-864.
15. Guvakova MA & Surmacz E 1997 Tamoxifen interferes with the insulin-like growth factor 1 receptor (IGF-IR) signaling pathway in breast cancer cells. Cancer Research 57 2606-2610.
16. Hennequin LF, Allen J, Curwen J, Fennell M, Green TP, Lambert-van der Brempt C, Morgentin R, Olivier R, Plé PA, Warin N et al. 2006. The discovery of N-(5-chloro-1,3-benzodioxol-4-yl)-7-[2-(4-methylpiperazin- 1-yl)ethoxy]-5-(tetrahydro-2H-pyran-4-yloxy)quinazolin-4-amine (AZD0530) a novel highly selective, orally available, dual-specific Src/abl kinase inhibitor. Journal of Medicinal Chemistry 2006 (in press).
17. Hiscox S, Morgan L, Barrow D, Dutkowskil C, Wakeling A & Nicholson RI 2004 Tamoxifen resistance in breast cancer cells is accompanied by an enhanced motile and invasive phenotype: inhibition by gefitinib ('Iressa', ZD1839). Clinical & Experimental Metastasis 21 201-212.
18. Hiscox S, Morgan L, Green TP, Barrow D, Gee J & Nicholson RI 2005 Elevated Src activity promotes cellular invasion and motility in tamoxifen resistant breast cancer cells. Breast Cancer Research and Treatment 1-12.
19. Hiscox S, Jiang WG, Obermeier K, Taylor K, Morgan L, Burmi R, Barrow D & Nicholson RI 2006 Tamoxifen resistance in MCF7 cells promotes EMT-like behaviour and involves modulation of beta-catenin phosphorylation. International Journal of Cancer 11897 290-301.
20. Irby RB & Yeatman TJ 2000 Role of Src expression and activation in human cancer. Oncogene 19 5636-5642.
21. Irby RB & Yeatman TJ 2002 Increased Src activity disrupts cadherin/catenin-mediated homotypic adhesion in human colon cancer and transformed rodent cells. Cancer Research 62 2669-2674.
22. Jackson JG, Yoneda T, Clark GM & Yee D 2000 Elevated levels of p66 Shc are found in breast cancer cell lines and primary tumors with high metastatic potential. Clinical Cancer Research 6 1135-1139.
23. Johnson FM, Saigal B, Talpaz M & Donato NJ 2005 Dasatinib (BMS-354825) tyrosine kinase inhibitor suppresses invasion and induces cell cycle arrest and apoptosis of head and neck squamous cell carcinoma and non-small cell lung cancer cells. Clinical Cancer Research 11 6924-6932.
24. Jones HE, Goddard L, Gee JM, Hiscox S, Rubini M, Barrow D, Knowlden JM, Williams S, Wakeling AE & Nicholson RI 2004 Insulin-like growth factor-I receptor signalling and acquired resistance to gefitinib (ZD1839; Iressa) in human breast and prostate cancer cells. Endocrine-Related Cancer 11 793-814.
25. Knowlden JM, Hutcheson IR, Jones HE, Madden T, Gee JM, Harper ME, Barrow D, Wakeling AE & Nicholson RI 2003 Elevated levels of epidermal growth factor receptor/c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cells. Endocrinology 144 1032-1044.
26. Kruger JS & Reddy KB 2003 Distinct mechanisms mediate the initial and sustained phases of cell migration in epidermal growth factor receptor-overexpressing cells. Molecular Cancer Research 1 801-809.
27. Kurokawa H & Arteaga CL 2001 Inhibition of erbB receptor (HER) tyrosine kinases as a strategy to abrogate antiestrogen resistance in human breast cancer. Clinical Cancer Research 7 4436s-4442s (Discussion 4411s-4412s).
28. Kurokawa H, Lenferink AE, Simpson JF, Pisacane PI, Sliwkowski MX, Forbes JT & Arteaga CL 2000 Inhibition of HER2/neu (erbB-2) and mitogen-activated protein kinases enhances tamoxifen action against HER2-over-expressing, tamoxifen-resistant breast cancer cells. Cancer Research 60 5887-5894.
29. Lilien J & Balsamo J 2005 The regulation of cadherin-mediated adhesion by tyrosine phosphorylation/dephosphorylation of beta-catenin. Current Opinion in Cell Biology 17 459-465.
30. Maa MC & Leu TH 1998 Vanadate-dependent FAK activation is accomplished by the sustained FAK Tyr-576/577 phosphorylation. Biochemical and Biophysical Research Communications 251 344-349.
31. Mao W, Irby R, Coppola D, Fu L, Wloch M, Turner J, Yu H, Garcia R, Jove R & Yeatman TJ 1997 Activation of c-Src by receptor tyrosine kinases in human colon cancer cells with high metastatic potential. Oncogene 15 3083-3090.
32. Masaki T, Okada M, Tokuda M, Shiratori Y, Hatase O, Shirai M, Nishioka M & Omata M 1999 Reduced C-terminal Src kinase (Csk) activities in hepatocellular carcinoma. Hepatology 29 379-384.
33. Masaki T, Igarashi K, Tokuda M, Yukimasa S, Han F, Jin YJ, Li JQ, Yoneyama H, Uchida N, Fujita J et al. 2003 pp60c-src activation in lung adenocarcinoma. European Journal of Cancer 39 1447-1455.
34. McClelland RA, Barrow D, Madden TA, Dutkowski CM, Pamment J, Knowlden JM, Gee JM & Nicholson RI 2001 Enhanced epidermal growth factor receptor signaling in MCF7 breast cancer cells after long-term culture in the presence of the pure antiestrogen ICI 182,780 (Faslodex). Endocrinology 142 2776-2788.
35. Moro L, Dolce L, Cabodi S, Bergatto E, Erba EB, Smeriglio M, Turco E, Retta SF, Giuffrida MG, Venturino M et al. 2002 Integrin-induced epidermal growth factor (EGF) receptor activation requires c-Src and p130Cas and leads to phosphorylation of specific EGF receptor tyrosines. Journal of Biological Chemistry 277 9405-9414.
36. Nam S, Kim D, Cheng JQ, Zhang S, Lee JH, Buettner R, Mirosevich J, Lee FY & Jove R 2005 Action of the Src family kinase inhibitor, dasatinib (BMS-354825), on human prostate cancer cells. Cancer Research 65 9185-9189.
37. Nicholson RI, Hutcheson IR, Harper ME, Knowlden JM, Barrow D, McClelland RA, Jones HE, Wakeling AE & Gee JM 2002 Modulation of epidermal growth factor receptor in endocrine-resistant, estrogen-receptor-positive breast cancer. Annals of the New York Academy of Sciences 963 104-115.
38. Nicholson RI, Staka C, Boyns F, Hutcheson IR & Gee JM 2004 Growth factor-driven mechanisms associated with resistance to estrogen deprivation in breast cancer: new opportunities for therapy. Endocrine-Related Cancer 11 623-641.
39. Nicholson RI, Hutcheson IR, Britton D, Knowlden JM, Jones HE, Harper ME, Hiscox SE, Barrow D & Gee JM 2005 Growth factor signalling networks in breast cancer and resistance to endocrine agents: new therapeutic strategies. Journal of Steroid Biochemistry and Molecular Biology 93 257-262.
40. Nollet F, Berx G & van Roy F 1999 The role of the E-cadherin/catenin adhesion complex in the development and progression of cancer. Molecular Cell Biology Research Communications 2 77-85.
41. Owen JD, Ruest PJ, Fry DW & Hanks SK 1999 Induced focal adhesion kinase (FAK) expression in FAK-null cells enhances cell spreading and migration requiring both auto- and activation loop phosphorylation sites and inhibits adhesion-dependent tyrosine phosphorylation of Pyk2. Molecular and Cellular Biology 19 4806-4818.
42. Parisot JP, Hu XF, DeLuise M & Zalcberg JR 1999 Altered expression of the IGF-1 receptor in a tamoxifen-resistant human breast cancer cell line. British Journal of Cancer 79 693-700.
43. Petit V, Boyer B, Lentz D, Turner CE, Thiery JP & Valles AM 2000 Phosphorylation of tyrosine residues 31 and 118 on paxillin regulates cell migration through an association with CRK in NBT-II cells. Journal of Cell Biology 148 957-970.
44. Pietras RJ, Arboleda J, Reese DM, Wongvipat N, Pegram MD, Ramos L, Gorman CM, Parker MG, Sliwkowski MX & Slamon DJ 1995 HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells. Oncogene 10 2435-2446.
45. Reynolds AB, Daniel JM, Mo YY, Wu J & Zhang Z 1996 The novel catenin p120cas binds classical cadherins and induces an unusual morphological phenotype in NIH3T3 fibroblasts. Experimental Cell Research 225 328-337.
46. Ring A & Dowsett M 2004 Mechanisms of tamoxifen resistance. Endocrine-Related Cancer 11 643-658.
47. Roura S, Miravet S, Piedra J, Garcia de Herreros A & Dunach M 1999 Regulation of E-cadherin/Catenin association by tyrosine phosphorylation. Journal of Biological Chemistry 274 36734-36740.
48. Schaller MD, Hildebrand JD, Shannon JD, Fox JW, Vines RR & Parsons JT 1994 Autophosphorylation of the focal adhesion kinase, pp125FAK, directs SH2-dependent binding of pp60src. Molecular and Cellular Biology 14 1680-1688.
49. Schlaepfer DD, Mitra SK & Ilic D 2004 Control of motile and invasive cell phenotypes by focal adhesion kinase. Biochimica et Biophysica Acta 1692 77-102.
50. Shupnik MA 2004 Crosstalk between steroid receptors and the c-Src-receptor tyrosine kinase pathways: implications for cell proliferation. Oncogene 23 7979-7989.
51. Slack JK, Adams RB, Rovin JD, Bissonette EA, Stoker CE & Parsons JT 2001 Alterations in the focal adhesion kinase/Src signal transduction pathway correlate with increased migratory capacity of prostate carcinoma cells. Oncogene 20 1152-1163.
52. Tang CK, Perez C, Grunt T, Waibel C, Cho C & Lupu R 1996 Involvement of heregulin-beta2 in the acquisition of the hormone-independent phenotype of breast cancer cells. Cancer Research 56 3350-3358.
53. Thomas SM & Brugge JS 1997 Cellular functions regulated by Src family kinases. Annual Review of Cell and Developmental Biology 13 513-609.
54. Thomas JW, Ellis B, Boerner RJ, Knight WB, White GC, II & Schaller MD 1998 SH2- and SH3-mediated interactions between focal adhesion kinase and Src. Journal of Biological Chemistry 273 577-583.
55. Tovey S, Dunne B, Witton CJ, Forsyth A, Cooke TG & Bartlett JM 2005 Can molecular markers predict when to implement treatment with aromatase inhibitors in invasive breast cancer? Clinical Cancer Research 11 4835-4842.
56. Tumbarello DA, Brown MC, Hetey SE & Turner CE 2005 Regulation of paxillin family members during epithelial-mesenchymal transformation: a putative role for paxillin delta. Journal of Cell Science 118 4849-4863.
57. Wells A, Kassis J, Solava J, Turner T & Lauffenburger DA 2002 Growth factor-induced cell motility in tumor invasion. Acta Oncologica 41 124-130.
58. Wheelock MJ & Johnson KR 2003 Cadherins as modulators of cellular phenotype. Annual Review of Cell and Developmental Biology 19 207-235.
59. Wiener JR, Windham TC, Estrella VC, Parikh NU, Thall PF, Deavers MT, Bast RC, Mills GB & Gallick GE 2003 Activated SRC protein tyrosine kinase is overexpressed in late-stage human ovarian cancers. Gynecologic Oncology 88 73-79.
60. Wilson CA & Slamon DJ 2005 Evolving understanding of growth regulation in human breast cancer: interactions of the steroid and peptide growth regulatory pathways. Journal of the National Cancer Institute 97 1238-1239.
61. Witters L, Engle L & Lipton A 2002 Restoration of estrogen responsiveness by blocking the HER-2/neu pathway. Oncology Reports 9 1163-1166.
62. Xing Z, Chen HC, Nowlen JK, Taylor SJ, Shalloway D & Guan JL 1994 Direct interaction of v-Src with the focal adhesion kinase mediated by the Src SH2 domain. Molecular Biology of the Cell 5 413-421.
63. Yap AS, Niessen CM & Gumbiner BM 1998 The juxtamembrane region of the cadherin cytoplasmic tail supports lateral clustering, adhesive strengthening, and interaction with p120ctn. Journal of Cell Biology 141 779-789.